Key facts
- Cellis’s last known valuation is $5.7M (Jan 2019).
- It has raised $13.3M; the latest was Later Stage VC ($29.6M) in Feb 2026.
- Notable investors include Horizon 2020, Twiti Investments.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Cellis
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellis
Developer of cell-based oncology therapies designed to improve cancer treatment outcomes for patients with unmet medical needs. The company offers a macrophage-based platform technology for targeting tumor microenvironments, enabling healthcare providers and oncology researchers to develop advanced immunotherapy treatments with improved therapeutic precision.
- Sector
- Healthcare
- HQ
- Warsaw, Poland
- Founded
- 2015
- Employees
- 20
- Website
- cellis.eu/
- Ownership
- Privately Held (backing)
Cellis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellis in its N-PORT filings yet. We sweep new filings monthly.